Lamegom

Agomelatine, the active ingredient in Lamegom, is a melatonergic antidepressant presented as a tablet for oral use. It treats major depressive disorder in adult patients. GNH USA supplies Lamegom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Agomelatine is a melatonergic antidepressant used primarily for major depressive disorder. - Major depressive disorder: reduces depressive symptoms and improves sleep quality. - Depression with disrupted circadian rhythm: helps resynchronize the biological clock. - Depressive episodes accompanied by insomnia: supports normalization of sleep‑wake patterns.

Adverse reactions may occur with agomelatine therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: transient gastrointestinal upset. - Dizziness: occasional light‑headedness. - Insomnia: difficulty initiating sleep. - Somnolence: increased daytime sleepiness. - Abdominal discomfort: mild stomach pain.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Stevens‑Johnson syndrome: rare severe skin reaction. - QT interval prolongation: potential cardiac arrhythmia.

Before initiating therapy, consider the following safety measures. - Liver function monitoring: assess transaminases before starting and periodically during treatment. - Contraindication in severe hepatic impairment: avoid use in patients with significant liver disease. - Mood monitoring: watch for emergence of suicidal thoughts, especially early in therapy. - CYP1A2 inhibitor avoidance: do not co‑administer strong inhibitors such as fluvoxamine. - Pregnancy and breastfeeding: use only if benefits outweigh potential risks. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Agomelatine may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP1A2 inhibitors (e.g., fluvoxamine): can raise agomelatine plasma levels. - CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce therapeutic effect. - Concurrent hepatotoxic agents: increase risk of liver injury.

Moderate Interactions (Monitor Closely): - CYP1A2 substrates (e.g., theophylline): may require dose adjustment. - Anticoagulants (e.g., warfarin): monitor INR for potential changes. - Other serotonergic drugs: observe for signs of serotonin syndrome.